tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avalo Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $24 price target The company’s lead asset, AVTX-009, is an anti-IL-1beta monoclonal antibody targeting inflammatory diseases, beginning with hidradenitis suppurativa, the analyst tells investors in a research note. The firm projects adjusted 2042 peak sales of $405M for AVTX-009 in HS alone, with additional upside from its potential application in other inflammatory diseases, such as inflammatory bowel disease. It believes Avalo “represents a compelling opportunity for long-term growth.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1